Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data - read this article along with other careers information, tips and advice on BioSpace
(0)
TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile
Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding
Phase 2a study demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage
Biogen to make a one-time payment of $18 million and may pay potential milestone payments and royalties to TMS Co., Ltd.
CAMBRIDGE, Mass. and FUCHU-SHI, Tokyo, May 12, 2021Inc (Nasdaq: BIIB) and TMS Co., Ltd. announced today that Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen s decision to acquire TMS-007 was based on positive data from a Phase 2a study. The study met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH) and demonstrated positive imp
Quake info: Unconfirmed quake Japan 20 Mar 2021 6:12 pm (GMT +9) - 129 user experience reports volcanodiscovery.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from volcanodiscovery.com Daily Mail and Mail on Sunday newspapers.